Pds Biotechnology Corp Stock Buy Hold or Sell Recommendation
| PDSB Stock | USD 1.23 0.03 2.38% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding PDS Biotechnology Corp is 'Cautious Hold'. Macroaxis provides PDS Biotechnology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding PDSB positions.
Check out PDS Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as PDS and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
PDS |
Execute PDS Biotechnology Buy or Sell Advice
The PDS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PDS Biotechnology Corp. Macroaxis does not own or have any residual interests in PDS Biotechnology Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PDS Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
PDS Biotechnology Trading Alerts and Improvement Suggestions
| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology may become a speculative penny stock | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PDS Biotechnology has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Life Science Virtual Investor Forum Presentations Now Available for Online Viewing |
PDS Biotechnology current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PDS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. PDS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
PDS Biotechnology Returns Distribution Density
The distribution of PDS Biotechnology's historical returns is an attempt to chart the uncertainty of PDS Biotechnology's future price movements. The chart of the probability distribution of PDS Biotechnology daily returns describes the distribution of returns around its average expected value. We use PDS Biotechnology Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PDS Biotechnology returns is essential to provide solid investment advice for PDS Biotechnology.
| Mean Return | -0.68 | Value At Risk | -9.22 | Potential Upside | 9.21 | Standard Deviation | 6.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PDS Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PDS Stock Institutional Investors
| Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 73.5 K | Two Sigma Investments Llc | 2024-12-31 | 65.7 K | Virtu Financial Llc | 2024-12-31 | 54.7 K | Ubs Group Ag | 2024-12-31 | 50.1 K | Vontobel Holding Ltd. | 2024-12-31 | 40 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 39 K | Jane Street Group Llc | 2024-12-31 | 35.6 K | Bank Of New York Mellon Corp | 2024-12-31 | 29.3 K | Bank Of America Corp | 2024-12-31 | 26.9 K | Vanguard Group Inc | 2024-12-31 | 1.5 M | Blackrock Inc | 2024-12-31 | 523.1 K |
PDS Biotechnology Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 16.7M | 36.4M | 8.6M | (17.3M) | (15.5M) | (14.8M) | |
| Free Cash Flow | (13.1M) | (12.5M) | (25.7M) | (33.6M) | (30.3M) | (31.8M) | |
| Depreciation | 15.6K | 5.4K | 86.0 | 17.4K | 15.6K | 14.8K | |
| Other Non Cash Items | 160.7K | 241.0K | 5.5M | 3.8M | 4.4M | 4.6M | |
| Net Income | (14.8M) | (16.9M) | (40.9M) | (42.9M) | (38.6M) | (40.6M) | |
| End Period Cash Flow | 28.8M | 65.2M | 73.8M | 56.6M | 65.0M | 61.8M | |
| Change To Netincome | (6.6M) | 613.0K | 4.4M | 5.2M | 6.0M | 6.3M |
PDS Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PDS Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PDS Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PDS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.61 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 6.25 | |
Ir | Information ratio | -0.09 |
PDS Biotechnology Volatility Alert
PDS Biotechnology Corp is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure PDS Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact PDS Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.PDS Biotechnology Fundamentals Vs Peers
Comparing PDS Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PDS Biotechnology's direct or indirect competition across all of the common fundamentals between PDS Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as PDS Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of PDS Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PDS Biotechnology to competition |
| Fundamentals | PDS Biotechnology | Peer Average |
| Return On Equity | -1.74 | -0.31 |
| Return On Asset | -0.45 | -0.14 |
| Current Valuation | 31.1 M | 16.62 B |
| Shares Outstanding | 44.59 M | 571.82 M |
| Shares Owned By Insiders | 3.10 % | 10.09 % |
| Shares Owned By Institutions | 9.57 % | 39.21 % |
| Number Of Shares Shorted | 3.87 M | 4.71 M |
| Price To Earning | 24.70 X | 28.72 X |
| Price To Book | 2.55 X | 9.51 X |
| EBITDA | (40.08 M) | 3.9 B |
| Net Income | (42.94 M) | 570.98 M |
| Cash And Equivalents | 52.98 M | 2.7 B |
| Cash Per Share | 1.86 X | 5.01 X |
| Total Debt | 23.85 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 12.34 X | 2.16 X |
| Book Value Per Share | 0.60 X | 1.93 K |
| Cash Flow From Operations | (33.64 M) | 971.22 M |
| Short Ratio | 6.07 X | 4.00 X |
| Earnings Per Share | (1.17) X | 3.12 X |
| Price To Earnings To Growth | (0.05) X | 4.89 X |
| Target Price | 10.13 | |
| Number Of Employees | 25 | 18.84 K |
| Beta | 1.67 | -0.15 |
| Market Capitalization | 54.85 M | 19.03 B |
| Total Asset | 59.39 M | 29.47 B |
| Retained Earnings | (144.5 M) | 9.33 B |
| Working Capital | 45.43 M | 1.48 B |
| Current Asset | 39.11 M | 9.34 B |
| Current Liabilities | 4.54 M | 7.9 B |
| Net Asset | 59.39 M |
Note: Acquisition by Glover Stephen C. of 15061 shares of PDS Biotechnology at 1.66 subject to Rule 16b-3 [view details]
PDS Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PDS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About PDS Biotechnology Buy or Sell Advice
When is the right time to buy or sell PDS Biotechnology Corp? Buying financial instruments such as PDS Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having PDS Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out PDS Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.